Catalyst Pharmaceuticals (CPRX) Tops Q4 EPS by 38c, Beats on Revenue; Offers FY25 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as higher oil prices temper risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Reddit to join S&P 500 index on Aug. 18, shares leap
- Should you chase this mini rally in gold? Citi weighs in
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
February 26, 2025 4:13 PM ESTFull Year 2024 Total Revenues of $491.7 Million, Marking Another Year of Record Growth
Full Year 2024 Total Revenues Grew 23.5% YoY, Driven by Strong Commercial Performance
Q4 2024 Net Product Revenue of $141.8 Million, Fueled by Sustained Organic Growth of FIRDAPSE® and Continued Market Adoption of AGAMREE®
Pursuing Strategic Investments to Expand Market Presence and Accelerate Growth
Full Year 2025 Total Revenues Expected to be Between $545 Million and $565 Million, Reflecting Confidence in Continued Growth Momentum
Conference Call and Webcast to be Held on February 27, 2025, at 8:30 AM... More
